Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Nan Fung Group Holdings Ltd

Q1 2024 · 13F-HR

Nan Fung Group Holdings Ltdholdings as filed

Filed 2024-05-14 · accession 0001012975-24-000206

$107.9M
Reported value
45
Positions
2024-03-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
452327109ILMNILLUMINA INC$16.4M15.2%119,196CommonSOLE
413197104HRMYHARMONY BIOSCIENCES HLDGS IN$12.4M11.5%368,665CommonSOLE
02083G100NVLSEURALPINE IMMUNE SCIENCES INC$10.5M9.69%263,940CommonSOLE
H5870P102OCSOCULIS HOLDING AG$5.3M4.87%436,378CommonSOLE
34385P108LABSTANDARD BIOTOOLS INC$5.1M4.73%1,883,179CommonSOLE
30223G102EXAIEUREXSCIENTIA PLC$4.9M4.56%859,892CommonSOLE
98420N105XENEXENON PHARMACEUTICALS INC$4.6M4.26%106,680CommonSOLE
374163103GERNGERON CORP$4.4M4.05%1,324,550CommonSOLE
45337C102INCYINCYTE CORP$4.2M3.91%74,022CommonSOLE
N5749R1002GHMERUS N V$4.0M3.73%89,516CommonSOLE
07725L102ONCBEIGENE LTD$3.6M3.34%23,022CommonSOLE
483497103KALVKALVISTA PHARMACEUTICALS INC$2.6M2.41%219,277CommonSOLE
54300N103LONGBOARD PHARMACEUTICALS IN$2.6M2.37%118,255CommonSOLE
604749101MIRMMIRUM PHARMACEUTICALS INC$2.4M2.24%96,100CommonSOLE
76243J105RYTMRHYTHM PHARMACEUTICALS INC$2.1M1.97%49,120CommonSOLE
04351P101ASNDUSDASCENDIS PHARMA A/S$2.1M1.90%13,600CommonSOLE
004225108ACADACADIA PHARMACEUTICALS INC$1.9M1.76%102,984CommonSOLE
76029N106REPLREPLIMUNE GROUP INC$1.7M1.55%204,939CommonSOLE
097702104BOLT1EURBOLT BIOTHERAPEUTICS INC$1.6M1.51%1,166,952CommonSOLE
753018100RANIRANI THERAPEUTICS HLDGS INC$1.5M1.42%493,584CommonSOLE
30161Q104EXELEXELIXIS INC$1.5M1.41%64,200CommonSOLE
558868105MDGLMADRIGAL PHARMACEUTICALS INC$1.5M1.41%5,682CommonSOLE
008064107AEROVATE THERAPEUTICS INC$1.4M1.31%47,936CommonSOLE
69404D108PACBPACIFIC BIOSCIENCES CALIF IN$1.0M0.95%274,488CommonSOLE
09061G101BMRNBIOMARIN PHARMACEUTICAL INC$944,5820.88%10,815CommonSOLE
640979100NMRANEUMORA THERAPEUTICS INC.$870,5810.81%63,315CommonSOLE
12674W109CABACABALETTA BIO INC$804,3790.75%47,150CommonSOLE
29384C108TRDAENTRADA THERAPEUTICS INC$695,4920.64%49,082CommonSOLE
09077A106BMEABIOMEA FUSION INC$598,0000.55%40,000CommonSOLE
04746L104ATHIRA PHARMA INC$493,2000.46%180,000CommonSOLE
89157D105TRMLTOURMALINE BIO INC$480,6020.45%20,987CommonSOLE
00166B105ALXOALX ONCOLOGY HLDGS INC$467,7430.43%41,950CommonSOLE
45258D105IMCRIMMUNOCORE HLDGS PLC$438,7500.41%6,750CommonSOLE
501575104KYMRKYMERA THERAPEUTICS INC$437,1750.41%10,875CommonSOLE
85205L107SWTXUSDSPRINGWORKS THERAPEUTICS INC$366,6890.34%7,450CommonSOLE
G76279101ROIVROIVANT SCIENCES LTD$342,2340.32%32,470CommonSOLE
23306J101DBV TECHNOLOGIES S A$277,8790.26%370,950CommonSOLE
76155X100RVMDREVOLUTION MEDICINES INC$235,2790.22%7,300CommonSOLE
00288U106ABCLABCELLERA BIOLOGICS INC$230,8990.21%50,971CommonSOLE
N01045207AFMDQAFFIMED N V$197,4090.18%37,247CommonSOLE
09058V103BCRXBIOCRYST PHARMACEUTICALS INC$187,1830.17%36,847CommonSOLE
50015M109KODKODIAK SCIENCES INC$167,9100.16%31,922CommonSOLE
N44445109IMTXIMMATICS N.V$165,0070.15%15,700CommonSOLE
31572Q808FGENEURFIBROGEN INC$145,9490.14%62,106CommonSOLE
36338D108GRTXGALERA THERAPEUTICS INC$85,8510.08%613,223CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.